As previously reported, Leerink downgraded Acadia Healthcare (ACHC) to Market Perform from Outperform with a price target of $14, down from $25. Each time Acadia reports earnings, more challenges emerge along with a continued deterioration in earnings, the analyst tells investors in a research note. Leerink says the size of the earnings guide-down from higher medical malpractice spending is surprising. The company’s operations continue to worsen, there’s “real risk” to its future legal liabilities, and its free cash flow is deteriorating contends Leerink. “We can no longer recommend this stock,” the firm adds.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- BofA downgrades Acadia Healthcare to Underperform after another guidance cut
- Acadia Healthcare downgraded to Underperform from Neutral at BofA
- Acadia Healthcare downgraded to Market Perform from Outperform at Leerink
- Acadia Healthcare price target lowered to $20 from $33 at Deutsche Bank
- Acadia Healthcare Stock (ACHC) Plunges on Guidance Cut